Hudson Bay Capital Management’s Verve Therapeutics VERV Stock Holding History

Hudson Bay Capital Management’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,747,598	Closed	-$19.6M	–	1705
2025 Q2	$19.6M	Buy	+1,747,598	New	+$9.96M	0.07%	217
2023 Q3	–	Sell	-22,500	Closed	-$422K	–	973
2023 Q2	$422K	Sell	22,500 -6,500	-22%	-$108K	﹤0.01%	636
2023 Q1	$418K	Buy	+29,000	New	+$568K	﹤0.01%	633

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Hudson Bay Capital Management's VERV Position: Q3 2025 in Review

Hudson Bay Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,747,598 shares — an estimated $19.6M sold.

Hudson Bay Capital Management first reported a position in VERV in Q1 2023 and held it in 3 quarters. The position peaked at $19.6M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Hudson Bay Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Hudson Bay Capital Management sold 1,747,598 Verve Therapeutics shares in Q3 2025, an estimated $19.6M.
Hudson Bay Capital Management first reported a position in Verve Therapeutics in Q1 2023 and held it in 3 quarters.
Hudson Bay Capital Management's Verve Therapeutics position peaked at $19.6M in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Hudson Bay Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.